Blog
RSS FeedPosted by Michael Wonder on 07 Apr 2022
NICE says new triple negative advanced breast cancer drug too expensive for NHS use
7 April 2022 - NICE has today issued draft guidance which does not recommend sacituzumab govitecan for treating locally advanced or ...
Posted by Michael Wonder on 07 Apr 2022
Hundreds of people with some forms of urothelial cancer to receive new treatment
7 April 2022 - Over 800 people with locally advanced or metastatic urothelial cancer are set to benefit from a new ...
Posted by Michael Wonder on 01 Apr 2022
Thousands of people set to benefit from first new treatment for osteoporosis for over a decade
1 April 2022 - Thousands of people in England and Wales with severe osteoporosis who are at high risk of fracture ...
Posted by Michael Wonder on 30 Mar 2022
Tagraxofusp for treating blastic plasmacytoid dendritic cell neoplasm
30 March 2022 - Tagraxofusp is human interleukin-3 genetically conjugated to diphtheria toxin protein. ...
Posted by Michael Wonder on 28 Mar 2022
Atidarsagene autotemcel for treating metachromatic leukodystrophy
28 March 2022 - NICE has published evidence-based recommendations on atidarsagene autotemcel (Libmeldy) for treating metachromatic leukodystrophy in children. ...
Posted by Michael Wonder on 24 Mar 2022
Nivolumab with ipilimumab for untreated advanced renal cell carcinoma
24 March 2022 - NICE has published evidence-based recommendations on nivolumab (Opdivo) with ipilimumab (Yervoy) for untreated advanced renal cell ...
Posted by Michael Wonder on 21 Mar 2022
NICE recommends elosulfase alfa for routine NHS use for patients with rare life-limiting metabolic disorder
21 March 2022 - NICE has today published final draft guidance recommending elosulfase alfa (Vimizim; BioMarin) for routine use in ...
Posted by Michael Wonder on 16 Mar 2022
Dostarlimab for previously treated advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency
16 March 2022 - NICE has published evidence-based recommendations on the use of dostarlimab (Jemperli) for the treatment of adults ...
Posted by Michael Wonder on 10 Mar 2022
Solriamfetol for treating excessive daytime sleepiness caused by obstructive sleep apnoea
9 March 2022 - NICE has published evidence based recommendations on the use of solriamfetol hydrochloride (Sunosi) for the treatment ...
Posted by Michael Wonder on 10 Mar 2022
Pitolisant hydrochloride for treating excessive daytime sleepiness caused by obstructive sleep apnoea
9 March 2022 - NICE has published evidence based recommendations on the use of pitolisant hydrochloride for the treatment of ...
Posted by Michael Wonder on 10 Mar 2022
Pegcetacoplan for treating paroxysmal nocturnal haemoglobinuria
9 March 2022 - NICE has published evidence based recommendations on the use of pegcetacoplan (Aspaveli) for the treatment of ...
Posted by Michael Wonder on 09 Mar 2022
Dapagliflozin for treating chronic kidney disease
9 March 2022 - NICE has published evidence based recommendations on dapagliflozin propanediol monohydrate (Forxiga) for adults with chronic kidney ...
Posted by Michael Wonder on 09 Mar 2022
Empagliflozin for treating chronic heart failure with reduced ejection fraction
9 March 2022 - NICE has published evidence based recommendations on the use of empagliflozin (Jardiance) for the treatment of ...
Posted by Michael Wonder on 09 Mar 2022
NICE unable to provide guidance on a new use of lenalidomide
9 March 2022 - NICE is unable to make a recommendation on the use of lenalidomide for the treatment of patients ...
Posted by Michael Wonder on 03 Mar 2022
Over 500 people a year can access a new life extending lung cancer treatment after NICE recommends its use within the Cancer Drugs Fund
3 March 2022 - An innovative life-extending drug for treating mutation-positive locally advanced or metastatic non-small-cell lung cancer in adults ...